Acadian Asset Management’s iTeos Therapeutics ITOS Stock Holding History

Acadian Asset Management’s Portfolio ITOS Stock Details ITOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-186,692	Closed	-$1.86M	–	1914
2025 Q2	$1.86M	Sell	186,692 -350,095	-65%	-$2.82M	﹤0.01%	849
2025 Q1	$3.2M	Buy	536,787 +66,641	+14%	+$489K	0.01%	622
2024 Q4	$3.61M	Buy	470,146 +453,245	+2,682%	+$3.89M	0.01%	609
2024 Q3	$172K	Buy	+16,901	New	+$258K	﹤0.01%	1415
2024 Q2	–	Sell	-244,712	Closed	-$3.34M	–	1832
2024 Q1	$3.34M	Buy	+244,712	New	+$2.67M	0.01%	555
2023 Q1	–	Sell	-23,159	Closed	-$451K	–	1847
2022 Q4	$451K	Sell	23,159 -238,407	-91%	-$4.66M	﹤0.01%	1064
2022 Q3	$4.98M	Sell	261,566 -29,173	-10%	-$672K	0.03%	397
2022 Q2	$5.99M	Buy	290,739 +164,540	+130%	+$3.9M	0.03%	367
2022 Q1	$4.06M	Buy	126,199 +118,702	+1,583%	+$4.31M	0.02%	508
2021 Q4	$347K	Buy	+7,497	New	+$250K	﹤0.01%	1103

Other funds holding ITOS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Acadian Asset Management's ITOS Position: Q3 2025 in Review

Acadian Asset Management sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 186,692 shares — an estimated $1.86M sold.

Acadian Asset Management first reported a position in ITOS in Q4 2021 and held it in 10 quarters. The position peaked at $5.99M in Q2 2022. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.

Acadian Asset Management reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
Acadian Asset Management sold 186,692 iTeos Therapeutics shares in Q3 2025, an estimated $1.86M.
Acadian Asset Management first reported a position in iTeos Therapeutics in Q4 2021 and held it in 10 quarters.
Acadian Asset Management's iTeos Therapeutics position peaked at $5.99M in Q2 2022.
1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.

Based on Acadian Asset Management's 13F filing for Q3 2025, filed 13 Nov 2025.